Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. Its operations are carried out through the following segments: CRO Business, Translational Research Business, Medipolis Business, and Others. he CRO business is a business that verifies the efficacy and safety of test substances created by clients such as pharmaceutical companies using laboratory animals, cells, and bacteria. The Translational Research Business segment utilizes drug and device development capabilities to accelerate drug development which leads to out-licensing to pharmaceutical companies. The Medipolis Business segment deals with the property management and geothermal power generation businesses. The Others segment engages in the information collection in Europe, which includes real estate and environmental equipment operations. The company was founded in April 1957 and is headquartered in Tokyo, Japan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company